

COGSTATE ENTERS INTO AGREEMENT WITH TECHNOLOGY COMPANY, CLINICAL INK, TO DELIVER ENHANCED TABLET-BASED NEUROPSYCHOLOGICAL ASSESSMENTS FOR CNS CLINICAL TRIALS

Medical Technology Company, Cogstate Ltd (ASX.CGS), today announced that it has signed an agreement with Clinical Ink, the leading provider of eSource and patient engagement technologies, to jointly deliver enhanced tablet-based neuropsychological assessments for Central Nervous System (CNS) clinical trials. The alliance allows the companies to offer Clinical Trial sponsors a single solution that combines the scientific and adult learning expertise provided by Cogstate with the market-leading eSource data capture platform from Clinical Ink.

The joint offering will enhance Cogstate's existing Scales Management & Rater Training offering, providing Cogstate's customers the benefits of electronic data capture for assessments of cognition that would otherwise be paper-based.

"Our goal is to transform the entire rater experience with process-enabling technologies that lead to better assessments, so a partnership with the eSource pioneers at Clinical Ink was the clear choice for advancing that objective", commented Cogstate CEO, Brad O'Connor. "This is one solution from two market leaders, so it is very much aligned to the 'best-of-breed' approach that many sponsors are taking for their outsourcing strategies; particularly in the area of CNS where signal detection is so challenging and endpoint quality assurance is so critical."

"The benefits of eSource for CNS research are dramatic," stated Ed Seguire, CEO, Clinical Ink. "Combining Cogstate's therapeutic expertise with our SureSource® platform, which directly captures data in the moment during the patient visit, promises to improve protocol execution. Researchers can focus more attention on the patient and the ratings when workflow and scoring are automated. This is an incredible time for CNS research and Clinical Ink is delighted to partner with a therapeutic leader like Cogstate on this advancement."

This joint solution delivers important advantages to clinical trial sponsors seeking to transcend traditional paper-and-pencil assessment scales in their trials, including:

- Custom edit checks, programmed workflows, and automated scoring at the point-of-care that prevent clerical errors and miscalculations
- Same day access to quality source data and documents for central monitoring by Cogstate's network of local expert advisors (LEADs), with custom flagging algorithms designed by clinical scientists for rapid identification of rater variance
- Rater training that reaches beyond the investigator meeting and eLearning platforms by elegantly incorporating rater guidance directly into the rating scale instrument used during the patient visit for more accurate, standardized administration
- A growing library of enhanced electronic scales ready for study-specific licensing and protocol customization

About Cogstate

Cogstate Ltd (ASX:CGS) is a leading cognitive science company dedicated to simplifying the measurement of cognition in clinical trials, academic research and healthcare. Cogstate provides expert support for traditional neuropsychological and functional assessments to drive higher quality measures, and commercializes rapid, reliable and highly sensitive computerized cognitive tests. Cogstate customers include the world's leading biopharmaceutical companies; military and elite sporting organizations; physicians and patients; renowned academic institutions and public-private partnerships.

www.cogstate.com

About Clinical Ink

Founded in 2007, Clinical Ink® is transforming clinical development with innovative eSource and patient engagement technologies that make clinical research easier for sites, sponsors and patients. Clinical Ink's SureSource® platform directly captures eSource data and documents from both patients and sites while improving protocol execution and data quality. Clinical Ink maintains offices in Cambridge, MA, Winston-Salem, NC, and Philadelphia, PA.

www.clinicalink.com.

For further information contact:

Brad O'Connor

Cogstate Chief Executive Officer

+613 9664 1300 or 0411 888 347

boconnor@cogstate.com